1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
    Meeting Abstract

    Rosenberg, J.; Necchi, A.; Sweis, R. F.; Nakajima, K.; Lu, C.; Nogai, H.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Chowdhury, S.; McDermott, R.; Piulats, J. M.; Shapiro, J. D.; Mejlholm, I.; Morris, D.; Ostler, P.; Hussain, A.; Dumbadze, I.; Goldfischer, E. R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)
    Meeting Abstract

    Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M. E.; Halabi, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial
    Meeting Abstract

    de Wit, R.; Kulkarni, G. S.; Uchio, E.; Singer, E. A.; Krieger, L.; Grivas, P.; Bajorin, D.; Seo, H. K.; Mourey, L.; Kamat, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
    Meeting Abstract

    McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Tripathi, A.; Supko, J. G.; Gray, K. P.; Melnick, Z.; Taplin, M. E.; Choudhury, A. D.; Pomerantz, M.; Bellmunt, J.; Yu, C.; Sun, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Sahai, V.; Catenacci, D. V. T.; Murphy, A.; Vaccaro, G.; Paulson, A.; Oh, D. Y.; Féliz, L.; Lihou, C.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Blanc, J. F.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Cicin, I.; Chen, Y.; Bolondi, L.; Dadduzio, V.; Baron, A.; Lin, Z. Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer
    Meeting Abstract

    Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Ohtsu, A.; Tabernero, J.; Ilson, D. H.; Hyung, W. J.; Strong, V. E.; Goetze, T. O.; Yoshikawa, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save